Cytovia Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • PIPE
  • (Announced)
  • Financing Rounds
  • 5
  • Investments
  • 3

Cytovia General Information

Description

Operator of a biopharmaceutical company intended to address several of the unmet medical needs in oncology. The company's bio-medicines and drugs include a patented drug screening technology that discovers and develops small-molecule inhibitors and activators of capsules, enabling the patients to fight cancer through stem cell engineering and multispecific antibodies.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly PE-Backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Parent Company
Primary Office
  • 18851 North East 29th Avenue
  • 2nd Floor
  • Aventura, FL 33180
  • United States
+1 (786) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Cytovia Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Cytovia‘s full profile, request access.

Request a free trial

Cytovia Patents

Cytovia Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-7732468-B2 3-(3-ethyl-1-methyl-1h-pyrazol-5-yl)-6-p-tolyl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole; to treat ameliorating neoplasia; cancers; infectious viral disease, autoimmune disease; rheumatoid arthritis; inflammatory diseases; skin diseases like psoriasis Expired - Fee Related 15-Nov-2006 00000000000
US-20080113984-A1 3-(3-ethyl-1-methyl-1h-pyrazol-5-yl)-6-p-tolyl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole; to treat ameliorating neoplasia; cancers; infectious viral disease, autoimmune disease; rheumatoid arthritis; inflammatory diseases; skin diseases like psoriasis Granted 15-Nov-2006 00000000000 0
CA-2657931-A1 3-aryl-6-aryl-7h-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and analogs as activators of caspases and inducers of apoptosis and the use thereof Abandoned 18-Jul-2006 000000000
US-20080045514-A1 3-aryl-6-aryl-7h-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and analogs as activators of caspases and inducers of apoptosis and the use thereof Abandoned 18-Jul-2006 000000000 0
EP-2046336-A4 3-aryl-6-aryl-7h-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and analogs as activators of caspases and inducers of apoptosis and the use thereof Withdrawn 18-Jul-2006 A61K31/53 0
To view Cytovia’s complete patent history, request access »

Cytovia Executive Team (15)

Name Title Board Seat Contact Info
Olivier Gouédard Chief Operating Officer
Wei Li Ph.D Chief Scientific Officer
Armin Rath Co-Founder & Vice President, Business Development & Alliance Management
Anna Baran-Djokovic Co-Founder & Vice President, Investor Relations & Capital Markets
Gilles Seydoux Co-Founder, Acting Chief Business Officer, Corporate Secretary and Board Member
You’re viewing 5 of 15 executive team members. Get the full list »

Cytovia Board Members (7)

Name Representing Role Since
000000 0000000 Cytovia Co-Founder, Acting Chief Business Officer, Corporate Secretary and Board Member 000 0000
00000 00000 Self Board Member 000 0000
0000000 000000 00.0 Self Board Member & Co-Founder 000 0000
0000000 00000000 00.0 Self Co-Founder & Board Member 000 0000
0000000 00000000 00 Self Co-Founder and Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Cytovia Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Cytovia‘s full profile, request access.

Request a free trial

Cytovia Investments & Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 000 26-Apr-2022 0000000000 Special Purpose Acquisition Company (SPAC) 000000 00
00000000 0000 13-Sep-2021 00000 0000 0000 Biotechnology 000000 00
CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR) 03-Aug-2020 Corporate Asset Purchase Buildings and Property 000000 00
To view Cytovia’s complete investments and acquisitions history, request access »